AR049545A1 - Cis-imidazolinas - Google Patents

Cis-imidazolinas

Info

Publication number
AR049545A1
AR049545A1 ARP050101998A ARP050101998A AR049545A1 AR 049545 A1 AR049545 A1 AR 049545A1 AR P050101998 A ARP050101998 A AR P050101998A AR P050101998 A ARP050101998 A AR P050101998A AR 049545 A1 AR049545 A1 AR 049545A1
Authority
AR
Argentina
Prior art keywords
group
lower alkyl
lower alkoxy
nx8x9
substituted
Prior art date
Application number
ARP050101998A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR049545A1 publication Critical patent/AR049545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos, las sales y ésteres farmacéuticamente aceptables de los mismos que inhiben la interaccion de la proteína MDM2 con los péptidos similares al p53 y por ello tienen una actividad antiproliferante. Reivindicacion 1: Un compuesto de formula (1) y las sales y ésteres farmacéuticamente aceptables del mismo, en la que X1 se elige entre el grupo formado por alcoxi inferior y alcoxi inferior sustituido por trifluorometilo o fluor; X2 se elige entre el grupo formado por hidrogeno, halogeno, alquilo inferior y -C(X4X5)-X6; X3 se elige entre el grupo formado por hidrogeno, alcoxi inferior, halogeno y -C(X4X5)-X6; con la condicion de que cuando X2 es hidrogeno, halogeno o alquilo inferior, entonces X3 sea -C(X4X5)-X6; X4 y X5 son alquilo inferior y pueden estar unidos entre sí para formar un cicloalquilo; X6 se elige entre el grupo formado por alquilo inferior, ciano, -CH2-OH, -CH2-O-alquilo inferior, -CH2-O-alquilo inferior sustituido por alcoxi inferior, -C(O)X7 y -CH2-NX8X9; X7 se elige entre el grupo formado por hidroxi, alcoxi inferior, morfolino y -NX8X9; X8 y X9 se eligen con independencia entre sí entre el grupo formado por hidrogeno, alquilo inferior, alquilo inferior sustituido por alcoxi inferior o ciano y alcoxi inferior; Y1 e Y2 se eligen con independencia entre sí entre el grupo formado por halogeno, ciano y acetileno; R se elige entre el grupo formado por piperidinilo sustituido por un heterociclo de cinco o seis eslabones, piperidinilo sustituido por - NX8X9, y un resto de formula (2), en la que n = 1 o 2; R1 puede ser uno o varios sustituyentes elegidos entre el grupo formado por hidrogeno, oxo, alquilo inferior sustituido por R2, -C(O)R3 y -SO2-alquilo inferior; R2 se elige entre el grupo formado por hidroxi, alcoxi inferior, trifluorometilo, ciano, -NH-SO2-alquilo inferior, -NH-C(O)-alquilo inferior, -C(O)-alquilo inferior, -C(O)R4, -C(O)-NX8X9, -SO2-alquilo inferior, -SO2-NX8X9; R3 se elige entre el grupo formado por un heterociclo de cinco eslabones, alquilo inferior, alcoxi inferior y alquilo inferior sustituido por alcoxi inferior; y R4 se elige entre el grupo formado por hidroxi, alcoxi inferior, morfolino y -NX8X9.
ARP050101998A 2004-05-18 2005-05-16 Cis-imidazolinas AR049545A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57227504P 2004-05-18 2004-05-18
US61553404P 2004-10-01 2004-10-01
US66877205P 2005-04-06 2005-04-06

Publications (1)

Publication Number Publication Date
AR049545A1 true AR049545A1 (es) 2006-08-16

Family

ID=35058746

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101998A AR049545A1 (es) 2004-05-18 2005-05-16 Cis-imidazolinas

Country Status (21)

Country Link
US (2) US7964724B2 (es)
EP (1) EP1753727B1 (es)
JP (1) JP4814228B2 (es)
KR (3) KR20080027969A (es)
CN (1) CN1953965B (es)
AR (1) AR049545A1 (es)
AT (1) ATE414693T1 (es)
AU (1) AU2005243465B2 (es)
BR (1) BRPI0511328A (es)
CA (1) CA2565189A1 (es)
DE (1) DE602005011132D1 (es)
ES (1) ES2314660T3 (es)
IL (1) IL178884A (es)
MX (1) MXPA06013246A (es)
MY (1) MY143800A (es)
NO (1) NO20065730L (es)
PE (1) PE20060679A1 (es)
RU (1) RU2006144811A (es)
TW (1) TW200600501A (es)
WO (1) WO2005110996A1 (es)
ZA (1) ZA200609595B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
RU2411238C2 (ru) * 2005-03-16 2011-02-10 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
BRPI0619236A2 (pt) * 2005-12-01 2011-09-20 Hoffmann La Roche derivados de 2,4,5-trifenil imidazolina, composição farmacêutica que os compreende, uso e processo para a sìntese dos mesmos
KR101015073B1 (ko) * 2006-01-18 2011-02-16 에프. 호프만-라 로슈 아게 Ｍｄｍ2 억제제로서의시스-4,5-비아릴-2-헤테로시클릭-이미다졸린
EP2035416A1 (en) 2006-06-30 2009-03-18 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CN101541759A (zh) * 2006-11-27 2009-09-23 诺瓦提斯公司 取代的二氢咪唑类及其在治疗肿瘤中的用途
MX2009006397A (es) 2006-12-14 2009-08-13 Daiichi Sankyo Co Ltd Derivados de imidazotiazol.
EP2118123B1 (en) * 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008121767A2 (en) 2007-03-28 2008-10-09 President And Fellows Of Harvard College Stitched polypeptides
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
RU2487127C2 (ru) 2007-10-09 2013-07-10 Ф.Хоффманн-Ля Рош Аг Хиральные цис-имидазолины
WO2009151069A1 (ja) 2008-06-12 2009-12-17 第一三共株式会社 ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
DE102008047128A1 (de) 2008-09-15 2010-04-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen
MX2011007598A (es) 2009-01-16 2011-08-08 Daiichi Sankyo Co Ltd Derivados de imidazotiazol que tienen estructura de anillo de prolina.
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
KR20120099462A (ko) 2009-11-12 2012-09-10 더 리젠츠 오브 더 유니버시티 오브 미시건 스피로-옥신돌 ｍｄｍ2 길항제
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011106650A2 (en) * 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
WO2012021876A2 (en) 2010-08-13 2012-02-16 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2813256A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
UY33725A (es) 2010-11-12 2012-06-29 Sanofi Sa Antagonistas de mdm2 de espiro-oxindol
PL2684880T3 (pl) 2011-03-10 2018-07-31 Daiichi Sankyo Company, Limited Pochodna dispiropirolidyny
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
AU2012326026B2 (en) 2011-10-18 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocyles
US8987274B2 (en) 2011-10-28 2015-03-24 Merck Sharp & Dohme Corp Macrocycles that increase p53 activity and the uses thereof
WO2013080141A1 (en) 2011-11-29 2013-06-06 Novartis Ag Pyrazolopyrrolidine compounds
US9062071B2 (en) 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
JP6171003B2 (ja) 2012-05-24 2017-07-26 ノバルティス アーゲー ピロロピロリジノン化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
SG11201503052RA (en) 2012-11-01 2015-05-28 Aileron Therapeutics Inc Disubstituted amino acids and methods of preparation and use thereof
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX368703B (es) 2013-02-28 2019-10-11 Amgen Inc Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EP3412675A1 (en) 2013-05-27 2018-12-12 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
PT3004112T (pt) 2013-05-28 2017-12-11 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona e sua utilização no tratamento de doença
CN104208066B (zh) * 2013-06-03 2016-06-15 中国科学院遗传与发育生物学研究所 哌嗪衍生物作为p53分子调节剂的用途
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN105916857B (zh) 2013-11-21 2018-06-22 诺华股份有限公司 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2974449C (en) 2015-01-22 2023-08-29 Sanofi-Aventis Deutschland Gmbh Process for the production of 2-[4-(cyclopropanecarbonyl)phenyl]-2-methyl-propanenitrile
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
US11192898B2 (en) 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2019079677A1 (en) * 2017-10-20 2019-04-25 Corbus Pharmaceuticals, Inc. METHODS AND COMPOSITIONS RELATING TO 5- (1,1-DIMETHYLHEPTYL) -ORRESORCINOL ULTRAPUR
EP3863720A1 (en) 2018-10-08 2021-08-18 The Regents Of The University Of Michigan Small molecule mdm2 protein degraders
JP2023518423A (ja) 2020-03-19 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｍｄｍ２分解剤およびそれらの使用
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
US11548866B1 (en) 2021-11-22 2023-01-10 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
US11504381B1 (en) * 2021-11-22 2022-11-22 Ligature Therapeutics Pte. Ltd. Therapeutic compounds and methods of use thereof
KR20230087856A (ko) 2021-12-10 2023-06-19 교촌 에프 앤 비(주) 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02101065A (ja) 1988-10-06 1990-04-12 Tanabe Seiyaku Co Ltd イミダゾリン誘導体及びその製法
DE4203547A1 (de) * 1992-02-07 1993-08-12 Knoll Ag Verfahren zur racemattrennung von verapamil
FR2756560A1 (fr) * 1996-12-04 1998-06-05 Adir Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB2351082A (en) 1999-06-18 2000-12-20 Lilly Forschung Gmbh Synthesis of Cyclic Substituted Amidines
US6653501B2 (en) * 2001-06-27 2003-11-25 Napro Biotherapeutics, Inc. Chiral resolution method for producing compounds useful in the synthesis of taxanes
WO2003051359A1 (en) * 2001-12-18 2003-06-26 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
RU2312101C2 (ru) * 2001-12-18 2007-12-10 Ф.Хоффманн-Ля Рош Аг Цис-имидазолины в качестве ингибиторов mdm2

Also Published As

Publication number Publication date
KR100832277B1 (ko) 2008-05-26
IL178884A0 (en) 2007-03-08
IL178884A (en) 2010-12-30
KR20070011516A (ko) 2007-01-24
EP1753727B1 (en) 2008-11-19
MXPA06013246A (es) 2007-02-08
TW200600501A (en) 2006-01-01
EP1753727A1 (en) 2007-02-21
PE20060679A1 (es) 2006-08-11
JP4814228B2 (ja) 2011-11-16
ES2314660T3 (es) 2009-03-16
BRPI0511328A (pt) 2007-12-04
US7964724B2 (en) 2011-06-21
KR20080027969A (ko) 2008-03-28
ATE414693T1 (de) 2008-12-15
MY143800A (en) 2011-07-15
US20090143364A1 (en) 2009-06-04
DE602005011132D1 (de) 2009-01-02
JP2007538022A (ja) 2007-12-27
AU2005243465A1 (en) 2005-11-24
CN1953965A (zh) 2007-04-25
RU2006144811A (ru) 2008-06-27
CN1953965B (zh) 2012-07-04
US20050288287A1 (en) 2005-12-29
AU2005243465B2 (en) 2011-08-25
WO2005110996A1 (en) 2005-11-24
NO20065730L (no) 2007-01-19
KR20110033964A (ko) 2011-04-01
CA2565189A1 (en) 2005-11-24
ZA200609595B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
AR049545A1 (es) Cis-imidazolinas
AR053446A1 (es) Compuestos cis-2,4,5-triaril-imidazolinas y su uso como medicamento anti-cancer
AR042095A1 (es) Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
PE20061153A1 (es) Compuestos heterociclicos como inhibidores del factor viia
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
CO5680403A2 (es) Antagonistas de mchr1r
AR033623A1 (es) Amidas de acidos antranilicos, composiciones farmaceuticas que las contienen, asi como empleo para la manufactura de un medicamento
AR040475A1 (es) Espiropiperidinas o espiropirrolidinas triciclicas
AR049739A1 (es) Derivados de aril-piridina
PE20061144A1 (es) DERIVADOS DE PIRROLIDINA Y PIPERIDINA ACETILENO COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO METABOTROPICO (mGluRs)
AR035205A1 (es) Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
PE20040951A1 (es) Derivados ciclicos como moduladores de la actividad del receptor de quimiocina
PE20070462A1 (es) Compuestos derivados de fenilaminopropanol
UY28722A1 (es) Peptidos macrociclicos activos contra el virus del a hepatitis c
PE20071236A1 (es) Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
CO4970728A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
NO20054225L (no) Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister
AR034547A1 (es) Derivados de indolin-2-ona, su utilizacion, procedimiento para su preparacion, composicion farmaceutica que lo contiene, medicamento que consiste en dicho derivado, y un producto que contiene dicho derivado y un antagonista de los receptores de la vasopresina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal